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Hetero-oligosaccharides show a complex structure consisting of various saccharides, and are different from homo-polysaccharides such as starch, cellulose, and chitin, which are constructed of a simple monosaccharide. They are usually bound to proteins or lipids to form glycoconjugates in organisms. Though homo-polysaccharides play roles as energy sources and protective compounds, hetero-oligosaccharides are involved in various important biological phenomena, including cellular recognition, growth and differentiation, and the incidence of disease. This review deals with the elucidation of the structure and function of heterooligosaccharides in order to clarify their metabolic mechanisms from the viewpoint of applied microbiology and molecular cell biology. It also focuses on the many microbial enzymes involved in the biosynthesis and degradation of hetero-oligosaccharides, and their application in producing useful compounds. It describes in outline the results of this research.
I. Production of Aminosugar Nucleotides as Donors for Hetero-Oligosaccharide Synthesis Using Microbial Enzymes
Sugar nucleotides represent the activated forms of sugars that are incorporated into glycoconjugates and other macromolecules. They are involved in the interconversion of various sugars and in the biosynthesis of polysaccharides as compounds of activated glycosyl residues. In microorganisms, these nucleotides play important roles in the metabolism of the cell wall and membranes.
Since Leloir et al. first isolated uridine diphosphate glucose (UDP-Glc) from yeast, 1) a number of sugar nucleotides including uridine pyrophosphate linked to various sugars have been isolated from various sources. Cabib et al. isolated and identified as uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) a contaminating substance from a UDP-glucose preparation of yeast. 2) Further studies indicated that UDP-GlcNAc functions as a central compound in the interconversion of various aminosugars and as a precursor of aminosugar components of glycoconjugates. 3) Uridine diphosphate N-acetylgalactosamine (UDP-GalNAc), another aminosugar nucleotide, is synthesized enzymatically from UDP-GlcNAc by 4-epimerization. 4) The transformation of acetylhexosamine is similar to that of the glucosegalactose pair and is associated with UDP-glucose and UDP-galactose. It has been established that these aminosugar nucleotides are important precursors in the biosynthesis of the complex cell walls of microorganisms and various glycoconjugates on the cell membranes of animals.
In the course of studies of 5 0 -nucleotide metabolism in microorganisms, Tochikura et al. found that 5 0 -uridine monophosphate (5 0 -UMP) was converted to UDP-glucose at high yield by ground baker's yeast cells and by the acetone powder of brewer's yeast in the presence of glucose and a high concentration of inorganic phosphate. 5) They also found that large amounts of UDPGlcNAc were produced from 5 0 -UMP and glucosamine by dried baker's yeast cells in the presence of glucose, inorganic phosphate, and magnesium chloride 6) (Fig. 1 ). These fermentative methods are based on converting fermentative and respiratory energies to phosphorylate 5 0 -UMP and sugars using the complex enzyme systems of baker's yeast.
Enzymatic production of aminosugar nucleotides
We obtained large amounts of UDP-GlcNAc using the modified reaction system including 5 0 -UMP, glucosamine, glucose, and dried baker's yeast, as described above. After the reaction, UDP-GlcNAc was obtained at about 50% yield.
The enzymatic formation of UDP-GalNAc is catalyzed by UDP-GlcNAc 4-epimerase, which interconverts UDP-GlcNAc to UDP-GalNAc at a ratio of about 65:35 in Bacillus subtilis. 7) Enzymatic preparation of UDP-GalNAc from UDP-GlcNAc obtained by the above method was carried out using a crude epimerase from B. subtilis, followed by pyrophosphorolysis of residual UDP-GlcNAc with Staphylococcus aureus UDPGlcNAc pyrophosphorylase, which is inactive toward UDP-GalNAc (Fig. 1 ). This method depends on the action of the two enzymes, as follows:
The epimerase reaction was carried out at 37 C for 3 h. The maximum yield of UDP-GalNAc was reached in 60 min. It was equivalent to approximately 35% of the initial UDP-GlcNAc incubated. The reaction mixture of UDP-GlcNAc and UDP-GalNAc was treated with an enzyme preparation from S. aureus containing UDPGlcNAc pyrophosphorylase, which is specific toward UDP-GlcNAc. 9) Then the residual UDP-GlcNAc was subjected to pyrophosphorolysis, and was almost completely converted to UTP and GlcNAc-1-P. The UDPGalNAc formed was isolated using a Dowex 1X2 column (chloride form). The isolated compound was identified as UDP-GalNAc by various analytical methods. 10) 2. Application of UDP-GalNAc as a testing reagent for determination of a rare human blood group
We developed a novel method of detecting the rare type A blood group using UDP-GalNAc. The rare type A blood group takes the form of the type O blood group because its host has very weak N-acetylgalactosaminyl transferase activity in the serum, and therefore only a small amount of blood group A-antigen (GalNAc1-3(4)Gal-) is expressed on the surface of the blood cell. In the case of blood transfusion, this can have serious consequences if the host with the rare type A blood group is mistakenly judged to be of the normal type O blood group. Thus, it is necessary to have a test that can quickly and accurately determine whether the blood is of the rare type A group. We developed a practical testing method for detecting the rare type A blood group using UDP-GalNAc, as follows: Red blood cells from a normal type O blood group host were incubated with serum from a known rare type A blood host, and UDPGalNAc was used as the donor of GalNAc at 37 C for 2 h. During incubation, N-acetylgalactosaminyl transferase from the serum of the rare type A blood group host was expected to transfer GalNAc from UDPGalNAc to the blood group substance on the surface of the red blood cells from the normal type O blood group host. This in turn should result in agglutination with the anti-A antibody, although red type O blood cells do not normally agglutinate with anti-A antibody. When we examined the type A blood from many donors, we could easily identify the rare blood group by the degree of agglutination for anti-A antibody. We could detect any weak N-acetylgalactosaminyl transferase activity from type A blood as an estimate of the degree of agglutination against anti-A antibody. This should prove useful in establishing a novel and practical method of detecting rare group A blood using UDP-GalNAc.
II. Identification of Various Useful Glycosidases from Microorganisms for Analysis of Structure and Function of the Hetero-Oligosaccharide Chain in Glycoconjugates
Glycoconjugates such as glycoproteins and glycolipids are widely distributed as constituents of animal tissues, plants, and the cell walls and membranes of microorganisms. The sugar moieties of some glycoconjugates play key roles in cellular recognition and in the immune response. They are incorporated into the sugar chain of glycoconjugates by a reaction involving sugar nucleotides as donor substrates. On the other hand, glycosidases are useful for elucidating the structure, function, biosynthesis, and catabolism of the complex sugar chains in glycoconjugates.
Glycosidases can be broadly classified as exo-glycosidases and endo-glycosidases according to their specificities. Exo-glycosidases release the monosaccharide residue from the non-reducing end of a sugar chain, whereas endo-glycosidases release oligosaccharides from a sugar chain by cleaving at defined sites within it. In addition to cleaving glycosidic linkages, glycosidases also catalyze the synthesis of oligosaccharides by transglycosylation reactions. We found various glycosidases in the culture fluids of many microorganisms isolated from soil. As shown in Fig. 2 , they had the ability to hydrolyze most of the sugar chains found in glycoproteins and glycolipids.
Novel microbial endoglycosidases acting on glycoproteins and their applications
Two types of glycosidic linkages are generally present in glycoproteins. One comprises an N-acetylglucosamine linked N-glycosidically to an asparagine residue in the protein (the N-linked sugar chain), and the other involves an N-acetylgalactosamine linked glycosidically to the hydroxyl group of serine or threonine residues (the O-linked sugar chain). To elucidate the structure and function of these oligosaccharides in various glycoproteins, several chemical and enzymatic techniques are used. Among these, the use of a glycosidase in general and of an endoglycosidase in particular have proven to be highly convenient and indispensable tools for these purposes, because they can cleave at a defined site of linkage between an oligosaccharide and an aglycon, and can separate intact oligosaccharide and proteins and lipids from glycoconjugates under mild conditions without causing damage. 11) Endoglycosidases from microorganisms are useful because most of them have specific activity and can be obtained in large amounts.
Endo--N-acetylglucosaminidase (endo--GlcNAc-ase) hydrolytically cleaves the N,N 0 -diacetylchitobiose moiety in the core region of asparagine-linked oligosaccharides (N-glycosidically linked oligosaccharides) of various glycoproteins to release oligosaccharides. The enzyme is found mainly in the culture fluids of various microorganisms. Enzyme activity was first identified in the culture fluid of Diplococcus pneumoniae (Streptococcus pneumoniae).
12) Endo-H from Streptomyces griseus 13) is very popular among the endo--GlcNAc-ases of microorganisms.
We identified a Flavobacterium sp. bacterium isolated from soil and determined that it produced a high level of endo--GlcNAc-ase in the culture fluid. 14) High enzyme production was induced by the addition of yeast extract to the medium. 15) We examined the role of the sugar chain in various glycoenzymes (enzymes including a sugar chain) using this endo--GlcNAc-ase, because it was possible to obtain a considerable amount of deglycosylated enzymes, and thus we could compare the various properties of native glycoenzymes and deglycosylated ones. Using Flavobacterium sp. endo--GlcNAc-ase, we attempted to elucidate the roles of the sugar chains in glucoamylase from Rhizopus niveus, an important industrial enzyme in the production of glucose from starch.
16) The presence of the sugar chain in glucoamylase appeared to protect the protein from thermal denaturation and protease digestion.
17)
Endo--N-acetylgalactosaminidase (endo--GalNAcase) hydrolyzes the O-glycosidic linkage between -Nacetylgalactosamine and serine or threonine residues in glycoproteins to release a disaccharide, galactosyl-Nacetylgalactosamine. The enzyme has narrow substrate specificity and has been found in the culture broth of only a few microorganisms. It was first found by Huang and Aminoff in the culture filtrate of Clostridium perfringens as the enzyme responsible for destroying blood group specificity. 18) This was followed by identification of similar enzymes from several bacteria. 19, 20) Although these enzymes are useful for analyses of O-glycosidic linked oligosaccharides in glycoproteins, their sources are anaerobic and pathogenic bacteria, and thus they are difficult to produce for analytical purposes.
To find a better source of endo--GalNAc-ase, we examined the culture fluids of various bacteria isolated from soil, and we found an aerobic and non-pathogenic bacteria strain identified by us as Alcaligenes sp., produced this enzyme.
21) The disaccharide galactosyl -1,3 N-acetylgalactosamine, which is released by endo- -GalNAc-ase from glycoproteins, has been identified on the cell surface as a Thomsen-Friedenreich antigen (T-antigen) immune-determinant group. 22) T-Antigen is the immediate precursor of the human blood group MNantigen 23) and a distant precursor of groups found in other complex sugar chains, and is usually covered by covalently linked carbohydrates. In contrast, it has been found to be abundantly expressed in many carcinoma tissues. Hence, it has been proposed that the unmasked T-specific epitope is a unique tumor marker. 24) We proceeded to develop a sensitive method of detecting and determining the T-antigen by a combination of the use of Alcaligenes sp. endo--GalNAc-ase and HPLC. 25) The enzyme was allowed to react with Kato III cells, a human gastric carcinoma cell line that has been reported to contain T-antigen.
26) The carbohydrates produced in the enzymatic reaction mixture were derivatized with a pyridylamino reagent, and the resulting carbohydrate was found to be eluted at the same position as the pyridylamino-disaccharide standard on HPLC. Alcaligenes sp. endo--GalNAc-ase is considered to be useful for monitoring T-antigen in carcinoma cells.
III. Application of the Transglycosylation Activity of Microbial Endoglycosidases to the Synthesis of Bioactive Compounds
It is well known that many glycosidases exhibit transglycosylation activities that involve the transfer of a carbohydrate moiety to the hydroxyl groups of various compounds, in addition to their hydrolytic activities in the hydrolysis of glycosidic linkages. The transglycosylation activity of exoglycosidases is useful for the enzymatic synthesis of various oligosaccharides. 27) In contrast to the transglycosylation activities of exoglycosidases, those of endoglycosidases are less known and have not been well studied. Transglycosylation is considered to be a special type of hydrolysis. In the usual hydrolysis of glycosidases, the carbohydrate moiety of the substrate is released and transferred to water. On the other hand, during transglycosylation, the carbohydrate moiety released from the substrate is transferred to the hydroxyl groups of various compounds instead of water. 28) Thus, the transglycosylation activity of endoglycosidases can be useful in transferring and adding an oligosaccharide to various compounds having a hydroxyl group. These reactions are briefly described as follows:
Hydrolysis reaction of endoglycosidase:
Transglycosylation reaction of endoglycosidase:
Transglycosylation activity has attracted much attention in the field of glycotechnology as a very useful means of glycosylation. Although methods for the chemical synthesis of oligosaccharides have been developed, they are labor-intensive and involve complicated steps of protection and deprotection. The use of an endoglycosidase is an effective method of glycosylation of a compound to synthesize a glycoconjugate.
Transglycosylation reaction by endo--N-acetylglucosaminidase from Mucor hiemalis
Endo--N-acetylglucosaminidase (endo--GlcNAc-ase) hydrolyzes the N,N 0 -diacetylchitobiose (GlcNAc1-4GlcNAc) moiety in oligosaccharides bound to the asparagine residue of various glycoproteins and glycopeptides through an N-glycosidic linkage. It has a unique enzymatic action in that one GlcNAc residue remains bound to the protein/peptide. There are three types of asparagine-linked oligosaccharides found in glycoproteins: high-mannose, hybrid, and complex oligosaccharides. Some microbial endo--GlcNAc-ases identified in culture broths can hydrolyze either the high-mannose type or hybrid type oligosaccharide, or both.
11) However, they cannot entirely hydrolyze the complex oligosaccharides that are present in most animal glycoproteins. We have identified a fungus isolated from soil that produces endo--GlcNAc-ase, which can act to release complex oligosaccharides from glycoproteins 29) in addition to high-mannose and hybrid oligosaccharides. 30, 31) We identified this fungus as Mucor hiemalis, and named the enzyme Endo-M after its source.
32)
Endo-M has a specific transglycosylation activity. It transfers intact oligosaccharides from glycopeptides to suitable acceptors containing GlcNAc during the hydrolysis of glycopeptides. 33) Besides transferring complex sialo-bi-anntenary oligosaccharides, the enzyme is also capable of transferring high-mannose and hybrid oligosaccharides to the acceptor. Transglycosylation catalyzed by Endo-M is characterized as follows:
þ GlcNAc-Asn (R: any type of oligosaccharide, R 0 : peptide or peptide derivatives)
The transglycosylation activity of Endo-M can be used effectively to synthesize useful neoglycoproteins and neoglycopeptides containing oligosaccharides, because not every endo--GlcNAc-ase has transglycosylation activity. Hence, we attempted to use Endo-M for the syntheses of neoglycopeptides via the transglycosylation reaction of sialo complex oligosaccharides to synthetic peptides containing a GlcNAc moiety.
34)
2. Chemo-enzymatic synthesis of glycopeptides using Endo-M
We developed a practical method of synthesizing glycopeptides using a combination of the chemical synthesis of glycosyl peptides with an Endo-M enzymatic method of transglycosylation 35) (Fig. 3 ). Inazu and Kobayashi developed a convenient synthetic method to prepare the peptide with a GlcNAc group by solid-phase synthesis based on an Fmoc (9-fluorenylmethyloxycarbonyl) strategy in which Fmoc-N -(N-acetylglucosaminyl)-asparagine [Fmoc-(GlcNAc)Asn-OH] is used instead of Fmoc-Asn-OH. 36) Chemical synthesis of the peptide with a GlcNAc was carried out as follows: 37) Fmoc-(GlcNAc)Asn-OH was synthesized from 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-D-glucopyranosyl azide and N -Fmoc-Asp--t-butyl ester in the presence of triethylphosphine. Using Fmoc-(GlcNAc)Asn-OH as building block, solid-phase synthesis of a [(GlcNAc)Asn] peptide was performed by the dimethylphosphinothioic mixed anhydride (Mpt-MA) method. 38) The addition of oligosaccharides to the peptide containing GlcNAc was carried out making use of the transglycosylation activity of Endo-M. The reaction mixture was incubated at 37 C, and HPLC analysis of peptides and glycopeptides was done with a reversedphase column (Cosmosil 5C18AR, Nacalai Tesque, Japan).
Chemo-enzymatic synthesis of various bioactive glycopeptides
We prepared bioactive glycopeptides synthesized by the method described above as shown in Fig. 3 . The typical chemo-enzymatic synthesis of a bioactive glycopeptide is described below. 39) Peptide T is a bioactive peptide composed of eight amino acids with the sequence Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr that can block infection of human T cells by human immunodeficiency virus (HIV).
40) The first step in the chemoenzymatic synthesis of glycosylated Peptide T was the synthesis of N-acetylglucosaminyl Peptide T, which had GlcNAc attached to the Asn residue of the peptide by a solid-phase method. The second step was the addition of oligosaccharide from glycopeptides to N-acetylglucosaminyl Peptide T, [(GlcNAc) 6 Asn]Peptide T, using the transglycosylation activity of Endo-M. After separation by HPLC, glycosylated Peptide T was isolated. When native Peptide T and glycosylated Peptide T were incubated with Pronase (Actinase E), it was observed by analysis of HPLC that although almost all of the native Peptide T was degraded within 30 min, about 80% of the original amount of glycosylated Peptide T remained. 39) This suggests that glycosylated Peptide T is more stable against protease digestion than the native form.
Calcitonin is a calcium-regulating hormone composed of 32 amino acids. 41) This bioactive peptide is widely used as a therapeutic agent in the treatment of hypocalcemia, Paget's disease, and osteoporosis. Eel calcitonin contains no sugar chains, but does have a consensus sequence triplet (Asn-Xaa-Thr/Ser or AsnLeu-Ser) for N-glycosylation at the third to the fifth amino acid residue from the N-terminus. We attempted to add N-linked oligosaccharides artificially to the Asn residue of the peptide by a chemo-enzymatic method, since the biological addition of oligosaccharides is impossible. 42 ) N-Acetylglucosaminyl calcitonin was prepared by the Mpt-MA method, by which no protection of the sugar hydroxyl groups is used during peptide elongation. 38) Synthesis of calcitonin glycopeptides (glycosylated calcitonin) was performed using the transglycosylation activity of Endo-M to transfer a sialo complex oligosaccharide from human serum sialotransferrin glycopeptides to N-acetylglucosaminyl calcitonin. 43) In experiments in vitro, the calcitonin glycopeptides exhibited strong inhibitory activity toward the actin ring formation of osteoclast-like multinucleated cells. Although its activity was somewhat low in comparison with that of native calcitonin, the calcitonin glycopeptides exhibited sufficient inhibitory activity. 42) 4. Chemo-enzymatic synthesis of a glycopeptide containing a glutamine-linked sugar chain
The oligosaccharides in glycoproteins are linked to the asparagine residue in consensus sequence triplet Asn-Xaa-Ser/Thr, where Xaa is any amino acid but proline. This triplet sequence is necessary for glycosy- Fmoc-Asp-O t Bu, Fmoc-aspartic acid -t-butyl ester; Et3P, triethylphosphine lation, but it is possible to add an oligosaccharide to any Asn residue of a peptide by a chemo-enzymatic method. Furthermore, although biological addition of oligosaccharides to the glutamine residues of peptides is impossible, glycopeptides having a Gln-linked oligosaccharide can also be synthesized by this chemo-enzymatic method. Substance P is a bioactive undecapeptide and putative neurotransmitter that acts on the central and peripheral nervous systems.
44) It has no Asn residue, but has two Gln residues as the fifth and sixth amino acid residues from the N-terminus. An attempt to introduce an Nlinked oligosaccharide to the Gln residue of the peptide has been made by a chemo-enzymatic method. 45) Two Substance P derivatives with a GlcNAc attached to the fifth Gln residue and the sixth residue were synthesized by the solid-phase method by the Fmoc strategy. A building block Fmoc-N-acetylglucosaminyl glutamine, Fmoc-(GlcNAc)Gln-OH, was used instead of FmocGln-OH at the fifth or the sixth amino acid by the Mpt-MA method. After Substance P derivatives with GlcNAc were obtained, transglycosylation of N-linked oligosaccharides to the (GlcNAc)Gln moieties of Substance P derivatives was performed by catalysis with Endo-M in the manner described above. The glycosylated Substance P products were highly stable against peptidase digestion and were biologically active, although the activities were rather low. 45) We also prepared glycosylated -mating factor from yeast Saccharomyces cerevisiae via chemo-enzymatic synthesis by the addition of an oligosaccharide to the Gln residue of the peptide using the transglycosylation activity of Endo-M. 46) Glycosylated -mating factor exhibited higher resistance to proteolysis than the native -mating factor.
Enhancement of transglycosylation and glycosynthase-like activities using Endo-M mutants
Although Endo-M is the most promising tool for Nglycosylation, the yield of the transglycosylation product is low due to the inherent hydrolysis activity of the endoglycosidase for both the N-glycan of the donor substrate and the transglycosylation product. The ultimate solution to this problem is perhaps to develop unique endoglycosidase-based glycosynthase that lack hydrolysis activity toward the product but is able to accept a highly activated species as donor substrate. 47) For this purpose, we performed site-directed mutagenesis of Endo-M as a way to enhance its transglycosylation activity and/or to diminish its hydrolysis activity. First we carried out mutational studies on Endo-M to identify the critical residues necessary for the enzymatic activity. We found highly conserved Trp-228 to be essential for its transglycosylation activity, but not for its hydrolysis activity. 48) We also identified Glu-177 as putative proton donor. It is conserved in all other members of Glycoside Hydrolase (GH) family 85, as shown in the Carbohydrate-Active Enzyme (CAZy) database, and as shown by a comparison of the amino acid sequences of endo--GlcNAc-ases belonging to this family. 48) Endo--GlcNAc-ases of GH family 85 show transglycosylation activity, in contrast with endo--GlcNAc-ases of GH family 18, such as Endo-H and Endo-F, which show no transglycosylation activity. Although the crystal struc- 49, 50) no three-dimensional structures are available for the endoglycosidases of GH family 85. Only a preliminary X-ray crystallographic study of Endo-A (endo--GlcNAc-ase from Arthrobacter protophormiae) 51) belonging to GH family 85 is known (van Roey, P., personal communication). We used this information as a guide in performing site-directed mutagenesis of various residues in the putative catalytic region of Endo-M. Replacement of Tyr-217 with Phe caused enhanced transglycosylation activity over the wild type. 52) Kinetic analysis revealed that the K m value of the Y217F mutant for the acceptor substrate was one-tenth of that of the wild type, suggesting higher affinity of Y217F for the acceptor substrate than the wild type. These results suggest that removal of the hydroxyl group at Tyr-217 reduces steric hindrance and hydrophilicity, yielding favorable interaction and accommodation of the GlcNAc moiety in the acceptor at the catalytic site. Thus, Y217F was found to show both enhanced transglycosylation activity and diminished hydrolysis activity.
GH family 85 enzymes, including Endo-M, are assumed to catalyze hydrolysis and transglycosylation via an oxazolinium ion intermediate by a substrateassisted catalytic mechanism. 53) We have found that wild-type Endo-M can accept synthetic sugar oxazolines as donor substrates for transglycosylation. 53) Transglycosylation was particularly efficient when oxazolines of the N-glycan were used, since the resulting glycopeptide products were not hydrolyzed due to the modification of the enzyme, whereas the sugar oxazolines can still serve as excellent donor substrates due to their highly activated nature and their ability to mimic the transition state. 52) Hence, to examine the transglycosylation potential of the Endo-M mutants using sugar oxazolines corresponding to native N-glycans, first we synthesized a sugar oxazoline corresponding to the natural highmannose type N-glycan Man 9 GlcNAc 2 -Asn, which was prepared from soybean flour by a method described by Wang et al. 54) This sugar oxazoline was used as donor substrate in examining transglycosylation with wild-type Endo-M and mutants of it, in which a GlcNAc-pentapeptide derived from erythropoietin was used as acceptor substrate. We found that the mutant Y217F exhibited much higher transglycosylation activity toward the Man 9 GlcNAc-oxazoline than wild-type Endo-M did. Under the same reaction conditions, the yield of the transglycosylation product reached 50% using the mutant Y217F, whereas the wild-type Endo-M gave a maximum of 8% of the transglycosylation product. 52) Although the Y217F mutant possessed effective transglycosylation activity with sugar oxazolines, the transglycosylation products were still subject to enzymatic hydrolysis during transglycosylation.
For GH18 chitinases and GH20 -N-acetylhexosaminidases, a substrate-assisted catalytic mechanism has been proposed, in which the 2-acetamido substituent acts as a nucleophile to form an oxazolinium ion intermediate. 55, 56) In this substrate-assisted mechanism, a conserved acidic residue (usually Asp) located 1 or 2 amino acid residues upstream of the proton donor residue is identified. This assists in appropriate orientation of the 2-acetamido group for catalysis, and can also stabilize the transition state flanking the oxazolinium ion intermediate. 55, 56) Endo-M might proceed by a similar substrate-assisted mechanism, since this enzyme is known to be able to use synthetic sugar oxazolines as donor substrates for transglycosylation. 53) In GH85 enzymes, a highly conserved Asn residue (Asn-175 in Endo-M) may play the same role as the corresponding Asp residue in GH18 chitinases and GH20 -Nacetylhexosaminidases. Thus, upon protonation at the anomeric oxygen, the Asn-175 residue in Endo-M assists in appropriately orienting the 2-acetamido group, promoting the nucleophilic attack of the 2-acetamido group at the anomeric position to form the oxazolinium ion intermediate that proceeds further to hydrolysis and transglycosylation. It was found that the mutation at Asn-175 knocked out hydrolysis activity, but the mutant was able to use the highly active sugar oxazolines as donor substrates for transglycosylation. Thus, in combination with a sugar oxazoline, mutant N175A acted as a glycosynthase for glycosidic bond formation, allowing accumulation of the transglycosylation product (Fig. 4) . However, it was found that the rate of transglycosylation with mutant N175A was much lower than that of the wild-type Endo-M or mutant Y217F. Thus, to improve further the catalytic efficiency of the glycosynthase for practical use, we performed systematic mutagenesis at the critical Asn-175 site of Endo-M. 57) We tried to replace this residue with the other 19 natural amino acid residues, except for proline. Of these, N175Q showed extraordinarily high transglycosylation activity, with an initial rate about 9 times and 1.5 times higher than those of N175A and the wild-type enzyme respectively. This enhanced transglycosylation activity together with its reduced product hydrolysis activity makes N175Q a valuable mutant for glycoconjugate synthesis. 57) 
Application of the Endo-M mutant in the synthesis of glycosylated compounds
To demonstrate the usefulness of N175Q with a sugar oxazoline for the synthesis of sialo-glycopeptides containing a complex sialo-oligosaccharide, the sperm antigen CD52, Substance P, and PAMP 12 were synthesized using N175Q and sugar oxazoline derivatized (NeuAc-Gal-GlcNAc-Man) 2 -Man-GlcNAc 2 -Asn as a complex sialo-oligosaccharide. 58) We prepared this sialylated complex sugar oxazoline by a new synthetic method that directly converts the GlcNAc at the reducing end to an oxazoline using 2-chloro-1,3-dimethylimidazolinium chloride (DMC) in an aqueous solution without the need for protection and deprotection of the hydroxyl groups. 59) We sought to test the transglycosylation potency of N175Q toward a sialylated complex sugar oxazoline by glycosylation remodeling of the high-mannose type N-glycan of bovine pancreatic RNaseB into a sialocomplex type one. 58) First, the high-mannose type glycan was completely removed by Endo-H and GlcNAc-RNaseB was obtained. Then we carried out a transglycosylation reaction by the use of a sialo-complex sugar oxazoline as donor and GlcNAc-RNaseB as acceptor in the presence of N175Q. The transglycosylation reaction was assessed by SDS-PAGE. A band corresponding to GlcNAc-RNaseB (about 14 kDa) was rapidly shifted to a sialo-complex glycoform of RNaseB (about 16 kDa). 58) The results indicate that the highyield synthesis of a glycoprotein with a sialo-complex oligosaccharide can be achieved by the remodeling method using N175Q and one-step oxazoline synthesis.
Synthesis of a human influenza virus-binding inhibitor of a glycopolymer containing multivalent sialyl oligosaccharides
The chemo-enzymatic method using Endo-M was applied to the synthesis of a glycopolymer containing multivalent sialyl oligosaccharides. It is known that influenza viruses infect host cells through the binding of viral hemagglutinins to sialyl glycoproteins or sialyl glycolipids as receptors on the host cell surface.
60) The viruses recognize not only the sialic acids in the receptors but also particular structures in the sugar chain. These facts led us to attempt chemo-enzymatic synthesis of glycopolymers with polymeric compound backbones carrying multivalent sialo-oligosaccharides as inhibitors of infection by human influenza viruses. The sialyl glycopeptide from hen egg yolk is a suitable oligosaccharide donor for this purpose, because it has a sialyl 2-6 N-acetyllactosamine residue at the nonreducing end; this structure is known as the hemagglutinin receptor of the A-type influenza virus. 61) Hence it may prove useful as an inhibitor of infection by the influenza virus, although the binding ability of the sugar chain is not very strong. It is known that multivalent interactions occur between viral hemagglutinins and sialic acid on the cell surface, and that they are amplified by the so-called glycoside cluster effect. 62) Various synthetic glycopolymers carrying multivalent sialic acid residues that target viral hemagglutinins have been prepared as influenza virus inhibitors using various polymers as backbones. 63) These conventional glycopolymers inhibit the binding of influenza viruses to host cell receptors with high affinity.
We synthesized glycopolymers that mimic sialyl glycoproteins 64, 65) with the sialo-oligosaccharides clustered on a chitosan backbone. First we prepared pformylphenyl -GlcNAc using a phase-transfer catalytic system, and then we transferred a sialo-bi-anntenary complex oligosaccharide of glycopeptides from a hen egg yolk to this p-formylphenyl -GlcNAc using the transglycosylation activity of Endo-M. The compound obtained includes an aldehyde group that is able to condense with the amino group by reductive amination in aqueous solution. Then reductive amination of the pformylphenyl sialo-oligosaccharide with the chitosan backbone was carried out and a glycopolymer was obtained. Using this glycopolymer, we performed a hemagglutination inhibition test of the A-type influenza virus (the New Caledonia/20/99 strain), and found that the capacity for competitive inhibition was more 300-fold higher than fetuin as the control compound. 65) This result suggests that this glycopolymer is a very good inhibitor of influenza virus hemagglutination.
IV. Binding Specificity of Lactic Acid Bacteria to the Sugar Chain
Many viruses, pathogenic bacteria, and bacterial toxins specifically recognize and bind to carbohydrate moieties of the eukaryotic cell surface. 66) Their binding to the cells is essential in establishing an infection or producing a toxic effect. For intestinal bacteria, adherence to cell surfaces in colonizing epithelial tissues is an important initial event. They colonize the cell surface of the intestine to resist peristaltic movement and the flow of foods. Among such intestinal bacteria, the useful bacteria on the gut wall are associated with beneficial health effects for the host. 67) We speculated that useful intestinal bacteria are bound to the glycosphingolipids of the eukaryotic cell surface, because some pathogenic intestinal bacteria have been reported to bind particular glycosphingolipids for infection. 68) We focused on Lactobacillus because it is the most representative and useful one in the intestinal tract. It has been reported that urinary tract infections caused by uropathogenic Escherichia coli are prevented by implantation of Lactobacillus casei. 69) Hence we investigated the binding specificity of L. casei (IFO3425), which commonly inhabits animal intestines. 70) Various glycosphingolipids on a silica gel thin layer chromatography plate were developed and visualized with resorcinol reagent. Another developed plate was used for the binding assay, and was subjected to TLCimmunostaining by the use of a rabbit anti-L. casei IgG solution. Binding of the bacteria was quantitatively determined using a scanner and a computer. We found that L. casei bound strongly to trihexosylceramide (GbOse 3 Ceramide, CTH) and also to asialo-GM 1 (GgOse 4 Ceramide, GA 1 ) and lactosylceramide. The bacteria also bound to several glycosphingolipids with a relatively short sugar chain, but not to any ganglioside glycolipids with sialic acids in the oligosaccharides. 70) The glycosphingolipids necessary for the adhesion of L. casei have a common structure in that the nonreducing terminal saccharide in the sugar chain is a galactose moiety. Even though it has a different configuration of and , it appears to conform with the proposal that the galactosyl residue on the nonreducing terminal of the sugar chain is the minimal requirement for bacterial adhesion. On the other hand, the presence of sialic acid inhibited binding. The bacteria might be prevented from binding by uropathogenic E. coli, which have the ability to bind to CTH by competition with the receptor of glycosphingolipids.
V. Hetero-Oligosaccharide Catabolism of Bifidobacteria
The human gastrointestinal tract is inhabited by a vast and diverse community of microbes, and a well-balanced microflora is thought to be important for normal digestion and maintenance of the intestinal ecosystem. Among the complex intestinal microflora, bifidobacteria represent a ubiquitous commensal bacterial group in the gastrointestinal tract of humans and other animals. They are considered to be beneficial commensals for human health and one of the most useful probiotics, because they promote a healthy intestinal tract by preventing the growth of pathogenic bacteria by lowering the intestinal pH, and also by stimulating the host's immune system, enhancing anti-pathogenic and anti-carcinogenic activities. 71, 72) Bifidobacteria colonize the lower intestinal tract, an environment poor in mono-and di-saccharides, because sugars are preferentially consumed by the host and by microbes present in the upper intestinal tract. Thus, to survive in the lower intestinal tract, bifidobacteria appear to produce various exo-and endo-glycosidases in surface-bound and extracellular forms, by which they utilize diverse carbohydrates. 73, 74) 1. Bifidobacterial endo--N-acetylgalactosaminidase degraded the sugar chain of mucin glycoproteins
The epithelial cells of the human intestine express and secrete mucin glycoproteins, 75) which possess an abundance of O-glycosidic oligosaccharides. 76) We hypothesized that bifidobacteria act on mucin glycoproteins in the intestinal tract, thereby obtaining a source of energy.
We found that many bifidobacteria have a specific endoglycosidase, endo--N-acetylgalactosaminidase, which catalyzes the hydrolysis of the O-glycosidiclinkage between the sugar chain and a serine or threonine residue in mucin glycoprotein 77) (see chapter 2). To elucidate the function of this enzyme in bacteria, we carried out molecular cloning, expression, and characterization of an enzyme from Bifidobacterium longum JCM 1217. 78) Since the enzyme was found in the culture fluids of the bacteria, we searched for an uncharacterized hypothetical protein containing a secretion signal and a transmembrane domain using BLAST and Pfam HMM, and identified one potential sequence as an endo--GalNAc-ase. Then, using the sequence of the corresponding protein from B. longum NCC2705, the genome of which has been completely sequenced, 79) oligonucleotide primers were designed and a PCR product was amplified from the genomic DNA of B. longum JCM1217. This was confirmed to produce an endo--GalNAc-ase. The gene comprised an ORF of 5,901 bp encoding a protein of 1,966 amino acids. The coding sequence of endo--GalNAc-ase had no domains homologous to known glycoside hydrolase (GH) families in the Carbohydrate-Active Enzyme (CAZy) database. 80) Hence, a novel GH family 101 was established. We expressed a full-length His-tagged endo--GalNAc-ase in Escherichia coli BL21(DE3) and examined the substrate specificity of the recombinant enzyme using synthetic pNP substrates and natural glycoproteins. Analysis of the reaction mixtures indicated that a Gal1-3GalNAc disaccharide was liberated from asialofetuin, a natural glycoprotein, and a pNP substrate containing the core 1 substrate (Gal1-3GalNAc1-) . The enzyme also released unnatural Glc1-3GalNAc and GalNAc1-3GalNAc from the pNP-substrates, but did no act on the other pNP-core substrates (cores 2-8) 78) or sialofetuin. Thus, this enzyme might play an important role in the degradation and utilization of mucins with a core 1 O-glycan. Moreover, we solved the crystal structure of the catalytic domain of this enzyme and determined the structural basis of substrate recognition. 81) 2. Bifidobacterial glycosidases are involved in the catabolism of human milk oligosaccharides Generally, the intestines of breast-fed infants contain microflora that are dominated by bifidobacteria, in contrast to the contents of the intestines of formula-fed infants. 82, 83) It is widely accepted that oligosaccharides in human milk play a key role in the growth of bifidobacteria, 84, 85) because human milk contains a larger number of oligosaccharides than formula milk. Cow's milk contains lactose as almost the sole saccharide, and the major carbohydrate present in human milk too is lactose, but it contains more than 100 other oligosaccharides, 86) the building blocks of which contain the following three basic core disaccharides: lactose (Gal1-4Glc), lacto-N-biose I (LNB; Gal1-3GlcNAc), and N-acetyllactosamine (LacNAc; Gal1-4GlcNAc). 86) These are often modified by sialic acid and/or Lfucose. 85) The core structures of the human milk oligosaccharides (HMOs) other than lactose are classified into type I and type II, based on the disaccharide unit at the non-reducing end. Type I and type II oligosaccharides contain lacto-N-biose I and N-acetyllactosamine structures respectively at the non-reducing end. Type I oligosaccharides are predominant in HMOs, and type II oligosaccharides are minor components. Among them, 2 0 -fucosyllactose (Fuc1-2Gal1-4Glc, 2 0 FL), lacto-N-tetraose (Gal1-3GlcNAc1-3Gal1-4Glc, LNT), and lacto-N-fucopentaose I (Fuc1-2Gal1-3GlcNAc1-3Gal1-4Glc, LNFPI) are the most abundant components of HMOs, and the latter two are type I oligosaccharides. The domain of type I milk oligosaccharides is a specific feature of human milk, and is rarely found in other mammals. 87) To date, it remains unknown what structures constitute the growth-stimulating factors for bifidobacteria in human milk.
We found that some bifidobacteria have a unique metabolic pathway specific for LNB and galacto-Nbiose (GNB; Gal1-3GalNAc). GNB is the common Oglycan core structure in mucin glycoprotein and is the product released by endo--N-acetylgalactosaminidase. We carried out molecular cloning and characterization of various glycosidases involved in the metabolism of human milk oligosaccharides to achieve a better understanding of the catabolism of sugars by bifidobacteria.
The human intestinal tract secretes mucin glycoproteins including blood group substances. ABO blood group substances have an -1,2-L-fucosyl residue in common.
88) The mucin glycoproteins on the intestinal wall also appear to be rich in -1,2-L-fucosyl residues. We assumed that bifidobacteria might have the ability to degrade blood group substances in the mucin glycoproteins on the intestinal wall because they colonize the lower intestinal tract, which is poor in saccharides. Furthermore, core structures of HMOs are often modified by -1,2-L-fucosylation, and 1,2--L-fucosidase is required in order for bifidobacteria to utilize HMOs.
We found 1,2--L-fucosidase activity that was capable of cleaving an -1,2-L-fucosyl linkage in various strains of bifidobacteria, and we cloned the gene by screening a genomic library of B. bifidum JCM1254 for the ability to hydrolyze 2 0 -fucosyllactose. 89) The enzyme, expressed in E. coli, was a large protein with 1,959 amino acids, possessing a secretory signal sequence at the N-terminus and a membrane-anchoring motif at the C-terminus. The recombinant protein selectively hydrolyzed -1,2-linked L-fucosyl residues at the non-reducing end. It effectively liberated L-fucose from glycoproteins such as porcine stomach mucin, as well as blood-type antigens and HMOs such as lacto-Nfucopentaose I. The deduced amino acid sequence of the enzyme was entirely different from previously identified -L-fucosidases. In the CAZy database, the enzyme was classified into GH family 95, a new family created for it.
The crystal structure of the catalytic domain of the enzyme was also determined. 90) The overall structure consisted of four regions: an N-terminal region, a helical linker region, a helical barrel ð=Þ 6 domain, and a C-terminal region. The helical barrel ð=Þ 6 domain formed a catalytic pocket in which the fucosyl 1-2galactose moiety of 2 0 -fucosyllactose might lie. ii) -L-Fucosidase In addition to 1,2--L-fucosidase, bifidobacteria possess another cleaving enzyme that can act on the side chains of HMOs, an -1,3/4-fucosidase. The enzyme was isolated and cloned from B. bifidum JCM1254. 91 ) Its gene encoded a 1,493-amino acid polypeptide contain-ing an N-terminal signal sequence, a GH29 -Lfucosidase domain, a carbohydrate binding module (CBM) 32 domain, a found-in-various-architecture (FIVAR) domain, and a C-terminal transmembrane region, in that order. The recombinant enzyme expressed in E. coli was characterized. It specifically released -1,3-and -1,4-linked L-fucosyl residues from 3-fucosyllactose, various Lewis blood group substances, and lacto-N-fucopentaose II (Fuc1-4(Gal1-3)GlcNAc1-3Gal1-4Glc, LNFPII) and III (Fuc1-3(Gal1-4)GlcNAc1-3Gal1-4Glc, LNFPIII) in HMOs. It did not act on synthetic p-nitrophenyl -L-fucoside (pNP--L-Fuc). Its presence is presumably beneficial to bifidobacteria, as it can be used to unmask the core structure of HMOs so as to degrade them further.
iii) Sialidases In HMOs, there are many sialyl oligosaccharides modified by sialic acid on the non-reducing ends. Since sialic acid is a hindrance to many of the glycosidases involved in the degradation of HMOs, removal of sialic acid is necessary for bifidobacteria to assimilate HMOs. We discovered two sialidases from B. bifidum JCM1254, cloned their genes, and characterized the enzymes. 92) Sequence analysis revealed that the two sialidases had a signal peptide and a membrane anchor at the Nterminus and C-terminus respectively. One of these sialidases, SiaBb1, which comprised 1,795 amino acids, contained an esterase-like catalytic domain in addition to the sialidase catalytic domain. SiaBb2 consisted of 835 amino acids residues had a predicted molecular mass of 87 kDa. The enzyme must be a primitive form of sialidase, because it contained only a sialidase catalytic domain and is classified into GH family 33 except for its N-and C-terminus domains. SiaBb1 expressed in E. coli had esterase activity, as determined by using pNPacetate as substrate, confirming that it is a bi-functional protein. It released an acetyl residue from 9-O-acetyl sialic acid, one molecular species of sialic acid, suggesting that it has acetyl esterase activity. We hypothesized that SiaBb1 changes 9-O-acetyl sialic acid to sialic acid, which is easily degraded by normal sialidase. The recombinant SiaBb2 expressed in E. coli liberated sialic acids not only from sialyloligosaccharides but also from gangliosides, glycoproteins, and colominic acid. However, the linkage preference of the enzyme was remarkably biased toward the -2,3-linkage as opposed to the -2,6-and -2,8-linkages.
92)
iv) Lacto-N-biosidase We used cell suspensions of various bifidobacteria in order to study how bifidobacteria degrade HMOs. We identified several bifidobacteria strains with an enzyme that can release lacto-N-biose I (LNB) from lacto-Ntetraose (LNT), a major component of HMOs that includes a type I oligosaccharide. 93) Among bifidobacteria species known to be intestinal colonizers in infants, B. bifidum and B. longum had this enzyme ac!tivity, but no activities were detected in the other bifidobacteria or in other enteric bacteria, including clostridia, bacteroides, and lactobacilli. This indicates that of the bacteria that colonize infant intestines, only bifidobacteria have such enzyme activity. Hence, we cloned the gene encoding the enzyme, lacto-N-biosidase, from B. bifidum JCM1254 93) based on the amino acid sequence of the Streptomyces sp. strain 142 lacto-N-biosidase. 94) Analysis of the primary structure of the enzyme revealed that the protein consisted of 1,112 amino acids containing a signal peptide and a membrane anchor at the Nand the C-terminus respectively, and possessed a domain of GH family 20, CBM 32, and a bacterial immunoglobulin-like domain, in that order, from the Nterminus. To estimate the substrate preference of this enzyme, we used various pNP-sugars as substrates, and we found that the enzyme was most active towards pNP--lacto-N-bioside I (pNP--LNB) and less active towards pNP--galacto-N-biose (pNP--GNB) (30% as compared with pNP--LNB). The enzyme did not hydrolyze -linked disaccharides or any -linked pNPmonosaccharides, such as pNP--GlcNAc and pNP--GalNAc, and did not hydrolyze the fucosylated forms of LNT (lacto-N-fucopentaose I and II) or lacto-N-neotetraose (including type II oligosaccharide). These results indicate that the lacto-N-biosidase from B. bifidum has a substrate preference for unmodified -linked lacto-N-biose I (LNB), and suggests that some bifidobacterial strains are highly adapted to the utilization of HMOs with type I oligosaccharides. It is likely that bifidobacterial lacto-N-biosidase is a critical enzyme in the degradation of HMOs. v) GNB/LNB transporter Derensy-Dron et al. characterized a -1,3-galactosyl-N-acetylhexosamine phosphorylase (EC 2.4.1.211) in a cell-free extract of B. bifidum DSM20082 that has the ability to produce galactose-1-phosphate (Gal-1-P) and GlcNAc from LNB. 95) This enzyme also phosphorolyzed GNB, which is produced by endo--GalNAc-ase, to Gal-1-P and GalNAc. Kitaoka et al. purified the enzyme 96) and found that its N-terminal and internal amino acid sequences had high identity with a protein (BL1641) of B. longum NCC2705 whose genome sequence is available. 79) They cloned the homologous gene, lnpA, from type strain B. longum JCM1217 and confirmed that the gene encoded a -1,3-galactosyl-N-acetylhexosamine phosphorylase (GLNBP). 97) This suggests that bifidobacteria possess a specific transporter system to incorporate GNB and LNB, and that the catabolism of GNB from mucin glycoprotein is catalyzed by endo--GalNAc-ase, while that of LNB in HMOs is catalyzed by various HMO-cleaving enzymes, including lacto-N-biosidase in B. longum JCM1217. Kitaoka et al. also confirmed that three downstream genes of lnpA encode catalytic enzymes involved in the Leloir-like galactose pathway. 96) We confirmed the presence of ATP-binding cassette (ABC)-type sugar transporter genes located upstream of the lnpA gene of B. longum JCM1217. 97) Generally, the bacterial ABC transporter system includes a solute-binding protein that binds to substrates and delivers them to the membrane-associated transporter complex. Hence, we cloned the solute-binding protein gene of B. longum JCM1217, 97) expressed it (438 amino acids) in recombinant E. coli, and purified it. The protein (named GNB/LNB-binding protein, GL-BP) specifically bound GNB (K d ¼ 10 nM) and LNB (K d ¼ 87 nM) in an enthalpy-driven manner, as confirmed by isothermal titration calorimetry measurements. It did not bind to monosaccharides or other disaccharides, including LacNAc. It had the capacity to bind with LNT at a much higher K d value (11 mM), indicating that LNT is a poor ligand of GL-BP. These results indicate that several bifidobacterial strains can liberate LNB from type I HMOs through the action of lacto-N-biosidase and then import it using a GNB/LNB-specific transporter (Fig. 5) . We also determined the crystal structure of GL-BP, 98) and found that the interactions between GL-BP and the disaccharide ligands occurred mainly through watermediated hydrogen bonds. In comparison with the LNB complex, one additional hydrogen bond was found in the GNB complex. 97) vi) Glycosidases involved in the degradation of type II oligosaccharides in human milk
As described above, HMOs are composed of two major structures of type I and II oligosaccharides, including two core tetrasaccharides: lacto-N-tetraose (Gal1-3GlcNAc1-3Gal1-4Glc, LNT, type I oligosaccharide) and lacto-N-neotetraose (Gal1-4GlcNAc1-3Gal1-4Glc, LNnT, type II oligosaccharide). We identified the unique metabolic pathway of LNT in B. bifidum JCM1254, as described above. Then, in order to clarify the degradation pathway of LNnT in the same bifidobacteria, we cloned one -galactosidase (BbgIII) and two -N-acetylhexosaminidases (BbhI and BbhII), all of which are extracellular membrane-bound enzymes. 99) Recombinant BbgIII (1,935 amino acids) hydrolyzed LNnT into galactose and lacto-N-triose II (GlcNAc1-3Gal1-4Glc), but did not entirely hydrolyze LNT or LNB. Recombinant BbhI (1,627 amino acids), but not BbhII (1,060 amino acids), catalyzed the hydrolysis of lacto-N-triose II to GlcNAc and lactose. The hydrolysis rate for lacto-N-triose II was higher and the K m value was smaller than the other substrate containing a GlcNAc residue at the non-reducing end. In that BbgIII and BbhI were highly specific for LNnT and lacto-N-triose II respectively, they might play essential roles in cooperatively degrading the type II oligosaccharides of HMOs. 99) 3. Metabolic pathway of oligosaccharides in bifidobacteria Bifidobacteria are believed to have a special metabolic pathway for the production of galactosyl 1,3N-acetylgalactosamine (GNB), which is released from intestinal mucin glycoproteins by endo--N-acetylgalactosaminidase. They also have the ability to produce galactosyl 1,3N-acetylglucosamine (LNB) from human milk oligosaccharides given the involvement of various glycosidases, including extracellular sialidases, -Lfucosidases, and lacto-N-biosidase. The bacteria appear to import disaccharides into the cells through a specific transporter. The putative metabolic pathway of LNB/ GNB is shown in Fig. 5 . 100) Thus our results provide a basis for the development of new prebiotics.
Prebiotic effect of lacto-N-biose I on bifidobacterial growth
Non-digestible food ingredients that promote the growth and/or the activity of probiotics are called prebiotics. Several oligosaccharides, including raffinose, 101) fructo-oligosaccharide, 102) and galacto-oligosaccharide, 103) are known to function as prebiotics for bifidobacteria, and thus are specifically termed bifidus factors. We demonstrated the prebiotic effect of lacto-Nbiose I on bifidobacteria in vitro. 104) Pre-cultured cells were inoculated in GAM broth in the presence and the absence of 0.5% lacto-N-biose I. After 24 h of cultivation, cell growth was estimated. The addition of lacto-N-biose I enhanced the growth of many bifidobacteria, especially B. bifidum, B. breve, and B. longum, which are predominant in the intestines of breast-fed infants. In contrast to most of the bifidobacteria, the lactic acid bacteria, including Lactobacillus and Lactococcus, exhibited very weak or no significant change with the addition of lacto-N-biose I. Also, the remaining intestinal bacteria, Bacteroides, Clostridium, Enterococcus, Eubacterium, Propionibacterium, and Ruminococcus, were not significantly affected. 104) We have concluded that lacto-N-biose I is a highly specific natural prebiotic for bifidobacteria, which newborn infants receive for the first time from the colostrums of their mothers. We expect that lacto-Nbiose I supplementation will improve the quality of conventional synthetic milk.
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VI. Perspective
Microorganisms have various relations with heterooligosaccharides. Their cell walls and membranes consist of hetero-oligosaccharides, and they frequently come into contact with hetero-oligosaccharides produced by animals and plants. They can adapt to varying amounts of hetero-oligosaccharides by producing many enzymes that can utilize them or by recognizing them as binding sites. The perceived significance of heterooligosaccharides for microorganisms will probably continue to increase with further research. An understanding of the biological roles of hetero-oligosaccharides cannot be effectively pursued without an understanding of the associated microorganism glycosidases.
